CFO / Interim CEO
David Inman joined the DYSIS Medical team in March 2020. Prior to DYSIS, Mr. Inman was the VP of Finance and Accounting at Augmenix, Inc., which was sold to Boston Scientific at the end of 2018. Mr. Inman stayed at Boston Scientific until early 2020 as VP of Finance to help guide the successful transition and integration of the acquisition. Prior to Augmenix, Mr. Inman was with Haemonetics Corporation as head of Global Financial Planning & Analysis, and previously had held Finance, Marketing, New Business Development, and Strategic Planning roles at Boston Scientific Corporation and Staples, Inc. Mr. Inman earned a BA in Economics from the University of Pennsylvania, and an MBA in Finance and Strategic Management from The Wharton School at the University of Pennsylvania.